Bone Marrow Diseases
Welcome,         Profile    Billing    Logout  
 186 Companies   244 Products   244 Products   91 Mechanisms of Action   17 Trials   2576 News 


«12...89101112131415161718...5253»
  • ||||||||||  birinapant (IGM-9427) / IGM Biosciences
    Trial completion, Enrollment change, Combination therapy:  Birinapant With 5-azacitidine in MDS Subjects Who Are Na (clinicaltrials.gov) -  Apr 21, 2016   
    P1/2,  N=21, Completed, 
    Recruiting --> Completed | N=40 --> 2 | Trial primary completion date: Nov 2017 --> Mar 2016 Active, not recruiting --> Completed | N=45 --> 21
  • ||||||||||  foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
    Enrollment closed, Trial primary completion date, Metastases:  Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies (clinicaltrials.gov) -  Apr 20, 2016   
    P1/2,  N=49, Active, not recruiting, 
    N=70 --> 0 | Recruiting --> Withdrawn Completed --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Dec 2016
  • ||||||||||  Trial completion:  TevaGastrim for Stem Cell Mobilization Sibling Donors (clinicaltrials.gov) -  Apr 20, 2016   
    P2,  N=24, Completed, 
    Completed --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Dec 2016 Active, not recruiting --> Completed
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Trial completion, Metastases:  Nilotinib Pre and Post Allogeneic Stem Cell Transplantation (clinicaltrials.gov) -  Apr 20, 2016   
    P2,  N=24, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Enrollment closed, Enrollment change, Post-transplantation:  Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT (clinicaltrials.gov) -  Apr 13, 2016   
    P2,  N=200, Active, not recruiting, 
    Trial primary completion date: Aug 2017 --> Apr 2016 Recruiting --> Active, not recruiting | N=60 --> 200
  • ||||||||||  Trial completion:  T-Cell Depletion in Unrelated Donor Marrow Transplantation (clinicaltrials.gov) -  Apr 13, 2016   
    P3,  N=0, Completed, 
    Recruiting --> Active, not recruiting | N=60 --> 200 No longer recruiting --> Completed
  • ||||||||||  Trial completion:  Cord Blood Stem Cell Transplantation Study (COBLT) (clinicaltrials.gov) -  Apr 12, 2016   
    P2,  N=0, Completed, 
    No longer recruiting --> Completed No longer recruiting --> Completed
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Trial completion, Enrollment change:  Telemonitoring Study - for Chronic Myeloid Leukemia (CML) (clinicaltrials.gov) -  Apr 8, 2016   
    P=N/A,  N=14, Completed, 
    No longer recruiting --> Completed Active, not recruiting --> Completed | N=48 --> 14
  • ||||||||||  azacitidine / Generic mfg.
    Trial initiation date, Trial primary completion date, Combination therapy:  A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (clinicaltrials.gov) -  Apr 1, 2016   
    P1,  N=36, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015 Initiation date: Jun 2014 --> Feb 2015 | Trial primary completion date: Dec 2016 --> Aug 2017
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Enrollment closed, Enrollment change, Trial primary completion date:  Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies (clinicaltrials.gov) -  Mar 29, 2016   
    P2,  N=9, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=46 --> 9 | Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  volasertib (NBL-001) / Oncoheroes, Notable Labs
    Trial initiation date, Trial primary completion date:  VIAC: A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (clinicaltrials.gov) -  Mar 25, 2016   
    P1,  N=30, Not yet recruiting, 
    Recruiting --> Active, not recruiting | N=46 --> 9 | Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: Sep 2015 --> Jun 2016 | Trial primary completion date: Aug 2017 --> Dec 2017
  • ||||||||||  Campath (alemtuzumab) / Sanofi
    Trial primary completion date:  Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia (clinicaltrials.gov) -  Mar 24, 2016   
    P1,  N=24, Recruiting, 
    Initiation date: Sep 2015 --> Jun 2016 | Trial primary completion date: Aug 2017 --> Dec 2017 Trial primary completion date: Feb 2016 --> Feb 2017
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder (clinicaltrials.gov) -  Mar 21, 2016   
    P=N/A,  N=15, Terminated, 
    Completed --> Terminated; The study was terminated due to low enrollment. N=60 --> 15 | Withdrawn --> Terminated | Trial primary completion date: Mar 2010 --> Feb 2009; This study was stopped due to poor enrollment numbers
  • ||||||||||  PLX51107 / Daiichi Sankyo
    Enrollment open, Metastases:  A Study of PLX51107 in Advanced Malignancies (clinicaltrials.gov) -  Mar 17, 2016   
    P1,  N=60, Recruiting, 
    N=60 --> 15 | Withdrawn --> Terminated | Trial primary completion date: Mar 2010 --> Feb 2009; This study was stopped due to poor enrollment numbers Not yet recruiting --> Recruiting
  • ||||||||||  dasatinib / Generic mfg.
    Trial primary completion date:  Korean Post-marketing Surveillance for Sprycel (clinicaltrials.gov) -  Mar 9, 2016   
    P=N/A,  N=600, Recruiting, 
    Trial primary completion date: Feb 2016 --> Jul 2017 Trial primary completion date: Dec 2016 --> May 2016